title: [Surveillance of cytomegalovirus for antiviral efficacy and risk factors in allogeneic hematopoietic stem cell transplantation].
abstract: The study was aimed to investigate the pp65 antigen of human cytomegalovirus (CMV) and its clinical significance in patients revived allogeneic hematopoietic stem cell transplantation (HSCT). 104 patients received allogeneic HSCT were studied. Anticoagulant blood samples were obtained from the recipients before and after transplantation and in the convalescence. CMV pp65 antigen in leukocytes was detected by indirect immunofluorescence assay using CMV Brite Kit weekly. The results showed that among the 104 patients, 29 cases were CMV pp65 positive (27.88%). Out of 29 cases 16 were CMV antigenemia and 13 cases were CMV disease. There were 25 cases who positively responded to antiviral therapy (effective ratio 86.21%) and 4 cases died (case-fatality ratio 13.79%). The detection revealed a significant difference in the incidence of CMV infection between the patients received unrelated or haploidentical family donor HSCT (39.29%) and HLA-identical sibling donor HSCT (14.58%) (P < 0.05). The incidence rate of CMV infection in patients with 0-I grade aGVHD and patients with II-IV grade aGVHD were 19.44% and 46.88% respectively, which had significant difference (P < 0.05). There was significant difference in the occurrence of aGVHD between the patients with and without positive CMV pp65 (P < 0.05). It is concluded that infection of CMV can be detected by the CMV pp65 monoclonal fluorescence immunohistochemistry, The detection of CMV pp65 antigen in peripheral blood leukocytes as a indicator for CMV disease surveillance after HSCT, which may be used to early diagnose the CMV infection, to guide the antiviral treatment and evaluate its efficacy.
authors.affiliation: Beijing Daopei Hospital, Beijing 100039, China.
authors.forename: Jin-Song
authors.initials: JS
authors.lastname: Jia
authors.forename: Dong-Ping
authors.initials: DP
authors.lastname: Liu
authors.forename: Xiao-Jun
authors.initials: XJ
authors.lastname: Huang
authors.forename: Tong
authors.initials: T
authors.lastname: Wu
authors.forename: Dai-Hong
authors.initials: DH
authors.lastname: Liu
authors.forename: Yao-Chen
authors.initials: YC
authors.lastname: Zhang
authors.forename: Hong
authors.initials: H
authors.lastname: Su
authors.forename: Jing-Bo
authors.initials: JB
authors.lastname: Wang
authors.forename: Jia-Rui
authors.initials: JR
authors.lastname: Zhou
authors.forename: Qiang
authors.initials: Q
authors.lastname: Liu
authors.forename: Min-Yu
authors.initials: MY
authors.lastname: Ying
authors.forename: Rui-Juan
authors.initials: RJ
authors.lastname: Sun
authors.forename: Xuan
authors.initials: X
authors.lastname: Duan
authors.forename: Dao-Pei
authors.initials: DP
authors.lastname: Lu
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007962:Leukocytes / Q000821:virology; D008297:Male; D008875:Middle Aged; D010750:Phosphoproteins / Q000097:blood*; D012307:Risk Factors; D014763:Viral Matrix Proteins / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa